Clinical details of the cases included in the study
| Case ID∗ . | Diagnosis DLBCL . | Type . | Sex . | Age, y . | EBER . | EBNA2 %† . | ICOSL %† . | LMP1 . |
|---|---|---|---|---|---|---|---|---|
| 1 | IDD‡ | Non-GC | Male | 74 | + | 43 | <1 | + |
| 2 | IDD | Non-GC | Male | 71 | + | 65 | <1 | + |
| 3 | IDD | Non-GC | Male | 32 | + | 36 | <1 | + |
| 4 | IDD | Non-GC | Male | 56 | + | 45 | <1 | + |
| 5 | IDD | Non-GC | Male | 70 | + | 48 | <5 | + |
| 6 | IDD | Non-GC | Male | 71 | + | 40 | <1 | + |
| 7 | IDD | Non-GC | Female | 52 | + | 65 | <1 | + |
| 8 | IDD | Non-GC | Male | 83 | + | 70 | <1 | + |
| 9 | IDD | Non-GC | Male | 58 | + | − | >95 | + |
| 10 | IDD | Non-GC | Male | 59 | + | − | 20 | + |
| 11 | IDD | Non-GC | Male | 48 | + | − | 40 | + |
| 12 | IDD | Non-GC | Female | 86 | + | − | 60 | + |
| 13 | IDD | Non-GC | Female | 72 | + | − | 40 | + |
| 14 | IDD | GC | Male | 64 | − | − | 90 | − |
| 15 | NOSˆ | GC | Male | 83 | − | − | 50 | − |
| 16 | NOS | Non-GC | Male | 73 | − | − | 60 | − |
| 17 | NOS | Non-GC | Female | 83 | − | − | >90 | − |
| 18 | NOS | Non-GC | Male | 97 | − | − | 50 | − |
| 19 | NOS | GC | Female | 49 | − | − | 60 | − |
| 20 | NOS | GC | Male | 48 | − | − | >90 | − |
| 21 | NOS | GC | Female | 88 | − | − | >90 | − |
| 22 | NOS | Non-GC | Female | 50 | − | − | 20 | − |
| 23 | CTRL | R LN | − | − | 20 | − | ||
| 24 | CTRL | R LN | − | − | 20 | − |
| Case ID∗ . | Diagnosis DLBCL . | Type . | Sex . | Age, y . | EBER . | EBNA2 %† . | ICOSL %† . | LMP1 . |
|---|---|---|---|---|---|---|---|---|
| 1 | IDD‡ | Non-GC | Male | 74 | + | 43 | <1 | + |
| 2 | IDD | Non-GC | Male | 71 | + | 65 | <1 | + |
| 3 | IDD | Non-GC | Male | 32 | + | 36 | <1 | + |
| 4 | IDD | Non-GC | Male | 56 | + | 45 | <1 | + |
| 5 | IDD | Non-GC | Male | 70 | + | 48 | <5 | + |
| 6 | IDD | Non-GC | Male | 71 | + | 40 | <1 | + |
| 7 | IDD | Non-GC | Female | 52 | + | 65 | <1 | + |
| 8 | IDD | Non-GC | Male | 83 | + | 70 | <1 | + |
| 9 | IDD | Non-GC | Male | 58 | + | − | >95 | + |
| 10 | IDD | Non-GC | Male | 59 | + | − | 20 | + |
| 11 | IDD | Non-GC | Male | 48 | + | − | 40 | + |
| 12 | IDD | Non-GC | Female | 86 | + | − | 60 | + |
| 13 | IDD | Non-GC | Female | 72 | + | − | 40 | + |
| 14 | IDD | GC | Male | 64 | − | − | 90 | − |
| 15 | NOSˆ | GC | Male | 83 | − | − | 50 | − |
| 16 | NOS | Non-GC | Male | 73 | − | − | 60 | − |
| 17 | NOS | Non-GC | Female | 83 | − | − | >90 | − |
| 18 | NOS | Non-GC | Male | 97 | − | − | 50 | − |
| 19 | NOS | GC | Female | 49 | − | − | 60 | − |
| 20 | NOS | GC | Male | 48 | − | − | >90 | − |
| 21 | NOS | GC | Female | 88 | − | − | >90 | − |
| 22 | NOS | Non-GC | Female | 50 | − | − | 20 | − |
| 23 | CTRL | R LN | − | − | 20 | − | ||
| 24 | CTRL | R LN | − | − | 20 | − |
CTRL, control; IDD, immune deficiency/dysregulation; NOS, not otherwise specified; R LN, reactive lymph node.
A total of 22 cases of DLBCL from the Sapienza Rome and University of Siena Pathology Department archives. Five were GC types, and 17 were non-GC types, classified according to the Hans algorithm.
A total of 6 areas were manually counted, and in each area at least 100 cells were scored. The number in the table is the average percentage positive cells.
IDD per the World Health Organization lymphoma classification, fifth edition.